These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14557982)

  • 21. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs.
    Pancharoen C; Mekmullica J; Thisyakorn U; Kasempimolporn S; Wilde H; Herzog C
    Clin Infect Dis; 2005 Nov; 41(10):1537-40. PubMed ID: 16231271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules.
    López EL; Contrini MM; Xifró MC; Cattaneo MA; Zambrano B; Dumas R; Rouyrre N; Weber F
    Vaccine; 2007 Jan; 25(1):102-8. PubMed ID: 16914234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.
    Dagan R; Ashkenazi S; Livni G; Go O; Bagchi P; Sarnecki M
    Pediatr Infect Dis J; 2016 Jul; 35(7):e220-8. PubMed ID: 27093164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of immunology effects between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine].
    Wang X; Meng Z; Li R
    Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):422-4. PubMed ID: 11798797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up.
    Wang XY; Xu ZY; Ma JC; von Seidlein L; Zhang Y; Hao ZY; Han OP; Zhang YL; Tian MY; Ouyang PY; Zhang ZY; Han CQ; Xing ZC; Chen JC
    Vaccine; 2007 Jan; 25(3):446-9. PubMed ID: 16949710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course.
    Van Herck K; Van Damme P; Lievens M; Stoffel M
    J Med Virol; 2004 Feb; 72(2):194-6. PubMed ID: 14695659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study.
    Faridi MM; Shah N; Ghosh TK; Sankaranarayanan VS; Arankalle V; Aggarwal A; Sathiyasekaran M; Bhattacharya N; Vasanthi T; Chatterjee S; Choudhury J; Mitra M
    Indian Pediatr; 2009 Jan; 46(1):29-34. PubMed ID: 19179715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial.
    Jiang WP; Chen JT; Wang X; Wang YL; Liu Y; Chen WY; Xu WG; Qiu YZ; Yin WD
    Vaccine; 2008 Apr; 26(18):2297-301. PubMed ID: 18395305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
    Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
    Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries.
    Fukushima S; Kiyohara T; Ishii K; Nakano T; Hamada A
    Vaccine; 2017 Nov; 35(47):6412-6415. PubMed ID: 29029942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
    Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
    J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary study on immunologic effect of live attenuated hepatitis A vaccine (H2 strain) after booster dose].
    Wang X; Ma J; Zhang Y; Zhang Y; Han C; Xing Z; Chen J; Zhang Y; Zhao S; Gu H; Xu Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Apr; 21(2):124-7. PubMed ID: 11860772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis A vaccines and the elderly.
    Genton B; D'Acremont V; Furrer HJ; Hatz C; Louis Loutan
    Travel Med Infect Dis; 2006 Dec; 4(6):303-12. PubMed ID: 17098625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunogenicity and stability of an aluminum-free liposomal hepatitis A vaccine (Epaxal Berna)].
    Wegmann A; Zellmeyer M; Glück R; Finkel B; Flückiger A; Berger R; Just M
    Schweiz Med Wochenschr; 1994 Nov; 124(45):2053-6. PubMed ID: 7973542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.